Ribociclib (LEE011)

For research use only. Not for use in humans.

目录号:S7440 中文名称:瑞博西利,瑞博西林

Ribociclib (LEE011) Chemical Structure

CAS No. 1211441-98-3

Ribociclib (LEE011) 是一种具有口服活性的、高度特异性的CDK4CDK6抑制剂,对应的IC50值分别为10 nM和39 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2432.43 现货
RMB 1614.88 现货
RMB 4832.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ribociclib (LEE011)发表文献54篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Ribociclib (LEE011) 是一种具有口服活性的、高度特异性的CDK4CDK6抑制剂,对应的IC50值分别为10 nM和39 nM。Phase 3。
特性 口服生物有效的CDK4/6选择性抑制剂,处于Ⅲ期临床测试,用于晚期乳腺癌的治疗。
靶点
CDK4 [2]
(Cell-free assay)
CDK6 [2]
(Cell-free assay)
10 nM 39 nM
体外研究

LEE011是一种CDK4/CDK6的双重抑制剂,能够显著抑制17种神经细胞瘤中的12种的生长,平均IC50值是307 nM。对神经细胞瘤的抑制主要是抑制细胞的生长,受到G1细胞周期阻滞和细胞衰老的调控。

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DFSP105 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\tXVI1KGh? NWP0U3BoT0l3ME2yO|Yhdk1? NGT0V4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi1NlA2QCd-MkW4OVIxPTh:L3G+
Myoblast NGLxT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CySVczKGh? MojHTWM2OD1zMEO1JI5O MmfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
IMRS NVTKV5RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG0WG9bPzJiaB?= MmLsTWM2OD16N{Ogcm0> NU[zU2NwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
SKNAS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVewN2ZIPzJiaB?= NV7YUIU4UUN3MP-8olExODByIH7N NV\hN5JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
Rh28 NHLqc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHVO|IhcA>? MlrYTWM2OD16NEWgcm0> M1fqdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwN|c2Lz5{NUixNFM4PTxxYU6=
Rh41 NXHUWIhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp MkXNTWM2OD15MUi3JI5O NEjETFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFM4PSd-MkW4NVA{PzV:L3G+
CW9019 M1[wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ZWVczKGh? MXTJR|UxRTl7MUKgcm0> Mmj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh5 NUTyVFVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID0cGQ4OiCq Mk\2TWM2OO,:nkGwNFAxKG6P Mo\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh30 NFW0RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPTeVlCPzJiaB?= MkDuTWM2OO,:nkGwNFAxKG6P M4DrVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwN|c2Lz5{NUixNFM4PTxxYU6=
778 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy3NkBp NFv0NGNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NYLqXm9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
449 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi3NkBp NVXrWG9pcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP3 NH3tT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH6SJI4OiCq MVzpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXS5NJNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
LP6 NF\PV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\3eo44OiCq MYXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NIrHT3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUK3NkBp M1PHRolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NWjqOmlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
LPS141 NWP1RmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXWVXc4OiCq NYLu[|B[cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mn\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
778 NFO1O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLLN{4{OyEQvF2= Mon2NlQhcA>? MXjk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6gV{BxcGG|ZR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
449 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:zMlM{KM7:TR?= M17v[|I1KGh? MYnk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6gV{BxcGG|ZR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP3 M1O0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fyUVMvOzNizszN M4rOfVI1KGh? Morv[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJHMheGijc3W= MnnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP6 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3QcXY{NjN|IN88US=> NYDocYJFOjRiaB?= MkCy[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJHMheGijc3W= NYTzbnR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
LP8 NXfOSWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPNd5YxOy5|MzFOwG0> MWSyOEBp MnjM[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJHMheGijc3W= NVS5WpY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
LPS141 NUDNXWI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi1eHc{NjN|IN88US=> MXqyOEBp NULRbmpY\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U> NUfJXGlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
IMR5 NVLsVpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn5OHluOjRiaB?= MXjEUXNQ MlfqTWM2OD1zMk[gcm0> Ml7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
BE2C NXTidXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrYNlQhcA>? NELiOpFFVVOR M1\MNmlEPTB;MUO0JI5O M2DRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
1643 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjlNlQhcA>? NEX0bVdFVVOR NVWyRnB2UUN3ME2xOFchdk1? M{W2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
SKNSH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoizNlQhcA>? MVrEUXNQ MnTwTWM2OD1zNEigcm0> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
SY5Y NUfWPWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV2xXotMOjRiaB?= MV3EUXNQ MYPJR|UxRTF3NDDuUS=> NXLsUWJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NGP M33rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCyOEBp M1PoeGROW09? NH3nW4FKSzVyPUG3OUBvVQ>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
KELLY M3rmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxNlQhcA>? NHTEO3FFVVOR M4PzdmlEPTB;MkKwJI5O MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
CHP134 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzVPGlNOjRiaB?= MkfmSG1UVw>? MofNTWM2OD1{N{Ogcm0> M{\3R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NLF MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGyOEBp MknrSG1UVw>? NWHFU3pJUUN3ME2zNlghdk1? NHS0Zow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
LAN5 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPlNlQhcA>? NX7lO5ROTE2VTx?= NWLaNFVZUUN3ME20Nlkhdk1? NWG4T4lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NB69 NHjDXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjmeHJFOjRiaB?= Ml3uSG1UVw>? Mn3QTWM2OD15M{igcm0> NHfRUWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
SKNDZ MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvxNZFqOjRiaB?= M3excGROW09? MYLJR|UxRThyMTDuUS=> M4XKN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NBSD M{jwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37UfFI1KGh? MYTEUXNQ NFrSTYVKSzVyPUG5NFAhdk1? MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
SKNF1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPFbVAzPCCq NGrUe2tFVVOR MV3JR|UxRTN3MECgcm0> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
EBC1 M2G5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfidm8zPCCq M2npTGROW09? MoTETWM2OD14NECwJI5O NVXiV|dpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
SKNAS MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKyOEBp NFi5eVFFVVOR NFvx[3NKSzVy78{eNVAxODBibl2= M4Czb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NB16 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPMUYVOOjRiaB?= NWPadXFtTE2VTx?= NGTyUYdKSzVy78{eNVAxODBibl2= MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
RPE1 NY\GV4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f4UlI1KGh? MkjnSG1UVw>? MmDFTWM2OO,:nkGwNFAxKG6P NX[1bHlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
Sf21 M{jZeWZ2dmO2aX;uJIF{e2G7 NUnZWWl7OTBibXnudy=> NImwW29KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu0M2N6[2yrbj3EN{Bkdy2neIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z{MTDj[YxteyC3c3nu[{BT[iC|dXLzeJJifGViaX6gdJJme2WwY3Wgc4YhY2ejbX3hN|NRZUGWUDDh[pRmeiBzMDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE4xOTNizszNMi=> M{X2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
Sf21 M1HYWmZ2dmO2aX;uJIF{e2G7 NEXMdY8yOCCvaX7z NYKyOHJzUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKD[KaYOteIFo\2WmIFPET|kwS3mlbHnuMXQyKGOxLXX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC|ZkKxJINmdGy|IIXzbY5oKFCGS4Tp[IUhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYUOzVH1CXFBiYX\0[ZIhOTBibXnud{BjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNVk4KM7:TT6= MlLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
HepG2 NGfXZZVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkG0O|IhcHK| Ml;yRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR|UxKD1iMD6yPFYzKM7:TT6= NY\henlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
SEM MlnJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXHBN456PzJiaILz M{PXcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1XNJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkS2NFUh|ryPLh?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
KOPN8 NGXDTFBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NX7RflhqPzJiaILz NGHIRmpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvPVG45KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxVcXSncj3HcI8h[XO|YYmsJGVEPTBiPTCwMlUxODhizszNMi=> NY\1emM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
NCI-H1299 NFfkUHdEgXSxdH;4bYNqfHliYYPzZZk> NGLhTlk4OiCqcoO= MkK2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzMkm5JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFUvPDZizszNMi=> MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
T47D Ml7ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvwZYJwPzJiaILz NUGxbZFwT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPi5{Mkeg{txONg>? M13r[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D NUnBTGFIS3m2b4TvfIlkcXS7IHHzd4F6 MYq3NkBpenN? Mme5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB4LkKzJO69VS5? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
H1299 NGTvR5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF3ycXg4OiCqcoO= NFf5WIlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJOTJ7OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPy54M{eg{txONg>? NVn3eGxxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OVE6PzlpPkK4OlUyQTd7PD;hQi=>
KOPN8 NFL0O4ZCeG:ydH;zbZMh[XO|YYm= NXvaTYtZOC53IIXN NHm1b2g{KGi{cx?= NFPLV5RKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFvPVG45KGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBkdGWjdnXkJHBCWlBibHX2[Ywh[XRiMD61JJVOKGGodHXyJFMhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NVTHWYJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
KOPN8 MlnrRZBweHSxc3nzJIF{e2G7 NXTsfYtZOC53IIXN Ml;5NlQhcHK| NVjnZmVlUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLU3BPQCClZXzsd{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4Yh[2ynYY\l[EBRSVKSIHzleoVtKGG2IECuOUB2VSCycnWteJJm[XSnZDD3bZRpKE6DQzDmc5IhOSCqcjDhcoQhdWWjc4Xy[YQh[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Ml7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|UoRjJ7NEC3PVc2RC:jPh?=
Hep3B NWeyNmZrS2WubDDjfYNt\SCjc4PhfS=> M3fkU|I1KGi{cx?= MkjLR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTIVxO0JiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdyL1exJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7 NVjzR4lQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NVg{OTJpPkK5OVE5OzF{PD;hQi=>
HepG2 NFXQfHhE\WyuIHP5Z4xmKGG|c3H5 NF;STWQzPCCqcoO= M1ywSGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?= MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
A549 NWjP[WVzS2WubDDjfYNt\SCjc4PhfS=> MX6yOEBpenN? Mkf1R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzBxR{GgdIhie2ViYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enl? M4LVVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
NCI-H460 NGTyS49E\WyuIHP5Z4xmKGG|c3H5 NXrhWFNxOjRiaILz MY\D[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDOR2kuUDR4MDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
T47D NWDOPJU4S2WubDDjfYNt\SCjc4PhfS=> NW\yTYdmOjRiaILz NULyNJl6S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hXDR5RDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= M{jnWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
MDA-MB-231 MUPD[YxtKGO7Y3zlJIF{e2G7 MofuNlQhcHK| NYmwXm1SS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzBxR{GgdIhie2ViYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enl? Mn\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
Fluc-labeled 4T1 NV\Ee4FiSW62aYT1cY9zKGG|c3H5 NF;S[HMyOzBibXevb4c> M{e1[VE5KGSjeYO= NGn5e4FCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBud3W|ZTDGcJVkNWyjYnXs[YQhPFRzIHPlcIx{KGmvcHzhcpRm\CCrbjDCZYxjN2NibX;1d4Uh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJR2dW:{IIflbYdpfCCjdDCxN|AhdWdxa3esJIlxKGGmbXnubZN1\XKnZDDkZYltgSCob4KgNVgh\GG7czDt[YF{fXKnZDDh[pRmeiB6IITvJFI2KGSjeYO= M33LdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
T47D NUm3bmlDS2WubDDjfYNt\SCjc4PhfS=> MWeyOEBpenN? NUjHVVFMUW6mdXP0bY9vKG:oIHPlcIwh[3mlbHWgZZJz\XO2IHnuJIh2dWGwIGS0O2Qh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iR{CvS|EheGijc3WgZYNkfW23bHH0bY9vKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 NXr0OpdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OVE6PzlpPkK4OlUyQTd7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pRb(S807) / Rb / p53 / Cyclin E / Cyclin D1 / CDK4 / CDK6 / p27 / p21 / PARP; 

PubMed: 29789630     


Effect of ribociclib on pRB and G1 cell cycle regulating protein expressions in C666-1 and HK1 cells. Cells were treated with ribociclib in 2 concentrations, one of them near their corresponding IC50, for 24 and 48 hours. Phosphorylation of Rb in all cell䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕

29789630
Growth inhibition assay
Cell viability ; 

PubMed: 26390342     


Effects of palbociclib and ribociclib on viability of H157, H2170, H520 and H596 cells after 72 hours of drug treatment and IC50 values for inhibition of cell viability.

26390342
体内研究

LEE011 (200 mg/kg 每日,口服)引起小鼠中的BE2C 或者 1643细胞显著的生长延迟,没有体重减轻或者其它的毒性症状。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: BE2C, IMR5, 1643, SY5Y, CHP134, SKNSH, NGP, KELLY, LAN5, NLF, NB69, SKNDZ, NBSD, NBLS, SKNFI, EBC1, SKNAS, NB16, RPE1细胞系。
  • Concentrations: 10 μM
  • Incubation Time: ~100小时
  • Method:

    将板中优先附着基底生长的神经母细胞瘤细胞系以一式三份种植于Xcelligence实时细胞电子传感系统,用4个剂量梯度的抑制剂和DMSO为对照处理细胞24小时。连续监测细胞约100个小时,IC50通过以下方法测得:通过绘制细胞指数为时间的函数产生生长曲线,以在治疗开始时细胞指数为1作为标准。从治疗开始到处理96小时后,生长曲线下的面积通过基线下面积为1(治疗开始时的细胞指数)进行计算。积分面积以DMSO处理的对照组作为背景。抑制剂比上对照组的值取非线性对数值来计算。所有的实验至少重复一次。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: BE2C, NB-1643,或EBC1异种移植的小鼠。
  • Dosages: ~200毫克/千克 每天
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 7 mg/mL (16.1 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 434.54
化学式

C23H30N8O

CAS号 1211441-98-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04657679 Recruiting Drug: Ribociclib Breast Cancer Georgetown University|Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) March 2021 --
NCT04315233 Recruiting Drug: Ribociclib|Drug: Belinostat Metastatic Breast Cancer|Recurrent Ovarian Carcinoma University of Utah|Novartis|Acrotech Biopharma October 29 2020 Phase 1
NCT03834740 Recruiting Drug: Ribociclib|Drug: Everolimus Glioblastoma Multiforme|Glioma of Brain St. Joseph''s Hospital and Medical Center Phoenix|Ivy Brain Tumor Center|Barrow Neurological Institute December 21 2018 Early Phase 1
NCT03701334 Active not recruiting Drug: Ribociclib|Other: Endocrine Therapy Early Breast Cancer Novartis Pharmaceuticals|Translational Research in Oncology|Novartis December 7 2018 Phase 3
NCT03613220 Completed Drug: ribociclib|Drug: letrozole HR+ HER2 Breast Cancer Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

CDK Signaling Pathway Map

相关CDK产品

Tags: 购买Ribociclib (LEE011) | Ribociclib (LEE011)供应商 | 采购Ribociclib (LEE011) | Ribociclib (LEE011)价格 | Ribociclib (LEE011)生产 | 订购Ribociclib (LEE011) | Ribociclib (LEE011)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID